内源性大麻素在神经退行性疾病中的作用研究进展
Review of Research Progress on Endocannabinoids in Neurodegenerative Diseases
DOI: 10.12677/IJPN.2020.92003, PDF,   
作者: 朱时钰, 陆永利, 杨红卫*：三峡大学医学院生理与病理生理学系，湖北 宜昌
关键词: 内源性大麻素；大麻素受体；神经退行性疾病；Endocannabinoids； Endocannabinoid Receptor； Neurodegenerative Diseases
摘要: 神经退行性疾病(Neurodegenerative disease)是一类以神经元变性病变为基础的缓慢进展性疾病的总称，主要包括阿尔茨海默病(Alzheimer’s disease, AD)、帕金森病(Parkinson’s disease, PD)及肌萎缩侧索硬化症(amyotrophic lateral sclerosis, ALS)等。最近的研究发现内源性大麻素系统(endocannabinoid system, eCBs)可能是一种保护神经元免受伤害性刺激的内源性系统，对神经退行性疾病的病程有预防治疗作用。本文综述了eCBs对AD、PD及ALS的保护作用的几个方面，旨在为神经退行性疾病的治疗开辟新的策略和思路。
Abstract: Neurodegenerative diseases are characterized by slowly progressive degeneration and/or death of nerve cells. Examples of neurodegenerative diseases contain Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). Recent studies reveal that endocannabinoid system may be an endogenous system that protects neurons from harmful stimuli and may have a preventive and therapeutic effect on the neurodegenerative diseases. Here we summarized several aspects of the eCBs protective effect of the AD, PD and ALS, aiming at providing promising thera-peutic targets and new strategy for neurodegenerative diseases.
文章引用：朱时钰, 陆永利, 杨红卫. 内源性大麻素在神经退行性疾病中的作用研究进展[J]. 国际神经精神科学杂志, 2020, 9(2): 20-25. https://doi.org/10.12677/IJPN.2020.92003

参考文献

[1] Ohno-Shosaku, T., Tanimura, A., Hashimotodani, Y., et al. (2012) Endocannabinoids and Retrograde Modulation of Synaptic Transmission. Neuroscientist, 18, 119-132.
[Google Scholar] [CrossRef] [PubMed]
[2] Xu, J. and Chen, C. (2015) Endocannabinoids in Synaptic Plasticity and Neuroprotection. Neuroscientist, 21, 152-168.
[Google Scholar] [CrossRef] [PubMed]
[3] 朱时钰, 杨红卫. 大麻素2型受体在帕金森病中的神经保护作用研究进展[J]. 生命的化学, 2018, 38(4): 529-533.
[4] Scotter, E.L., Abood, M.E. and Glass, M. (2010) The Endocannabinoid System as a Target for the Treatment of Neurodegenerative Disease. British Journal of Pharmacol-ogy, 160, 480-498.
[Google Scholar] [CrossRef] [PubMed]
[5] Zhang, L., Wang, M., Bisogno, T., Di Marzo, V. and Alger, B.E. (2011) Endocannabinoids Generated by Ca2+or by Metabotropic Glutamate Receptors Appear to Arise from Different Pools of Diacylglycerol Lipase. PLoS ONE, 6, e16305.
[Google Scholar] [CrossRef] [PubMed]
[6] Raskin, J., Cummings, J., Hardy, J., Schuh, K. and Dean, R.A. (2015) Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Current Alzheimer Research, 12, 712-722.
[Google Scholar] [CrossRef] [PubMed]
[7] Chen, R., Zhang, J., Wu, Y., et al. (2012) Monoacylglycer-ol Lipase Is a Therapeutic Target for Alzheimer’s Disease. Cell Reports, 2, 1329-1339.
[Google Scholar] [CrossRef] [PubMed]
[8] Schmöle, A.C., Lundt, R., Toporowski, G., Hansen, J.N., et al. (2018) Cannabinoid Receptor 2-Deficiency AmelioratesDisease Symptoms in a Mouse Model with Alzheimer’s Dis-ease-Like Pathology. Journal of Alzheimer’s Disease, 64, 379-392.
[Google Scholar] [CrossRef] 
[9] Gauthier, A., Vassiliou, G., Benoist, F., et al. (2003) Adipocyte Low Density Lipoprotein Receptor-Related Protein Gene Expression and Function Is Regulated by Peroxisome Prolifera-tor-Activated Receptor γ. Journal of Biological Chemistry, 278, 11945-11953.
[Google Scholar] [CrossRef] 
[10] Tolón, R.M., Núñez, E., Pazos, M.R., et al. (2009) The Activation of Cannabinoid CB2 Receptors Stimulates in Situ and in Vitro Beta-Amyloid Removal by Human Macrophages. Brain Research, 1283, 148-154.
[Google Scholar] [CrossRef] [PubMed]
[11] Chen, X., Zhang, J. and Chen, C. (2011) Endocanna-binoid 2-Arachidonoylglycerol Protects Neurons against β-Amyloid Insults. Neuroscience, 178, 159-168.
[Google Scholar] [CrossRef] [PubMed]
[12] Wu, J., Bie, B., Yang, H., et al. (2013) Activation of the CB2 Receptor System Reverses Amyloid-Induced Memory Deficiency. Neurobiology of Aging, 34, 791-804.
[Google Scholar] [CrossRef] [PubMed]
[13] Wolff, M.C. and Leander, J.D. (2003) SR141716A, a Cannabinoid CB1 Receptor Antagonist, Improves Memory in a Delayed Radial Maze Task. European Journal of Pharmacology, 477, 213-217.
[Google Scholar] [CrossRef] [PubMed]
[14] Martin-Moreno, A.M., Brera, B., Spuch, C., et al. (2012) Prolonged Oral Cannabinoid Administration Prevents Neuroinflammation, Lowers Beta-Amyloid Levels and Im-proves Cognitive Performance in Tg APP 2576 Mice. Neuroinflammation, 9, 8.
[Google Scholar] [CrossRef] [PubMed]
[15] Ozaita, A., Puighermanal, E. and Maldonado, R. (2007) Regula-tion of PI3K/Akt/GSK-3 Pathway by Cannabinoids in the Brain. Journal of Neurochemistry, 102, 1105-1114.
[Google Scholar] [CrossRef] [PubMed]
[16] Giuffrida, A., Parsons, L.H., Kerr, T.M., et al. (1999) Dopa-mine Activation of Endogenous Cannabinoid Signaling in Dorsal Striatum. Nature Neuroscience, 2, 358-363.
[Google Scholar] [CrossRef] [PubMed]
[17] Marinelli, S, Di Marzo, V., Florenzano, F., Fezza, F., et al. (2007) N-Arachidonoyl-Dopamine Tunes Synaptic Transmission onto Dopaminergic Neurons by Activating Both Canna-binoid and Vanilloid Receptors. Neuropsychopharmacology, 32, 298-308.
[Google Scholar] [CrossRef] [PubMed]
[18] 邹梓良, 查运红, 杨红卫. 内源性大麻素系统与帕金森病关系的研究进展[J]. 广东医学, 2015, 36(9): 1449-1451.
[19] Kreitzer, A.C. and Malenka, R.C. (2005) Dopamine Modulation of State Dependent Endocannabinoid Release and Long-Term Depression in the Striatum. Neuroscience, 25, 10537-10545.
[Google Scholar] [CrossRef] 
[20] Venderova, K., Ruzicka, E., Vorisek, V. and Visnovsky, P. (2004) Survey on Cannabis Use in Parkinson’s Disease: Subjective Improvement of Motor Symptoms. Movement Disorders, 19, 1102-1106.
[Google Scholar] [CrossRef] [PubMed]
[21] Wong, P., Pardo, C., Borchelt, D., et al. (1995) An Adverse Property of a Familial ALS-Linked SOD1 Mutation Causes Motor Neuron Disease Charac-terized by Vacuolar Degeneration of Mitochondria. Neuron, 14, 1105-1116.
[Google Scholar] [CrossRef] [PubMed]
[22] Bruijn, L., Becher, M., Lee, M., et al. (1997) ALS-Linked SOD1 Mutant G85R Mediates Damage to Astro-Cytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions. Neuron, 18, 327-338.
[Google Scholar] [CrossRef] 
[23] Bilsland, L.G., Dick, J.R., Pryce, G., et al. (2006) In-creasing Cannabinoid Levels by Pharmacological and Genetic Manipulation Delay Disease Progression in SOD1 Mice. FASEB Journal, 29, 29.
[Google Scholar] [CrossRef] [PubMed]
[24] Kim, K., Moore, D.H., Makriyannis, A., et al. (2006) AM1241, a Cannabinoid CB2 Receptor Selective Compound, Delays Disease Pro-Gression in a Mouse Model of Amyotrophic Lateral Sclerosis. European Journal of Pharmacology, 542, 100-105.
[Google Scholar] [CrossRef] [PubMed]
[25] Zhao, P., Ignacio, S., Beattie, E.C., et al. (2008) Altered Pre-symptom-Atic AMPA and Cannabinoid Receptor Trafficking in Motor Neurons of ALS Model Mice: Implications for Excitotoxicity. European Journal of Neuroscience, 27, 572-579.
[Google Scholar] [CrossRef] [PubMed]
[26] Rossi, S., De Chiara, V., Musella, A., et al. (2010) Abnormal Sensitivity of Cannabinoid CB1 Receptors in the Striatum of Mice with Experimental Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis, 19, 1-8.
[Google Scholar] [CrossRef] [PubMed]
[27] Rothstein, J.D., Patel, S., Regan, M.R., et al. (2005) Be-ta-Lactam Antibiotics Offer Neuroprotection by Increasing Glutamate Transporter Expression. Nature, 433, 73-77.
[Google Scholar] [CrossRef] [PubMed]